Abstract
Research has identified the vasoconstrictors endothelin-1 (ET-1) and urotensin-II (U-II) as having a role in the development of atherosclerotic cardiovascular disease. We aimed to observe alterations in plasma levels of both ET-1 and U-II in patients with coronary heart disease (CHD) undergoing percutaneous transluminal coronary angioplasty (PTCA) and stent therapy from November 2006 through May 2007. We examined plasma levels of ET-1 and U-II in 40 patients with CHD and 40 age-matched healthy subjects by radioimmunoassay (RIA). Chi-square test, Student’s t-test, and one-way analysis of variance were used for statistical analyses. Correlations between variables were tested by simple linear regression analysis. Coronary heart disease patients had significantly higher ET-1 and UII levels than healthy controls (20.05 ± 4.65 vs 8.16 ± 3.38 and 71.90 ± 11.61 vs 20.89 ± 7.00 pg/ml, respectively, all P < 0.01). Importantly, plasma levels of U-II and ET-1 were correlated in patients with CHD (r = 0.64, P = 0.01). On day 1 after PTCA and stent therapy, plasma levels of ET-1 and U-II were significantly higher, by 99% and 25%, respectively, than those before therapy (all P < 0.01). On day 3 after therapy, ET-1 levels were higher by 25% (P < 0.01) than before therapy, and U-II levels decreased rapidly and were close to baseline levels (P > 0.05). On day 7 after therapy, CHD patients had significantly lower ET-1 and U-II levels than before therapy (all P < 0.01). Since ET-1 and U-II levels may be increased in plasma of patients with CHD, their activation might have clinical significance in terms of early intervention in patients with CHD, especially after PTCA and stent therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui T, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415
Sutherland AJ, Nataatmadja MI, Walker PJ, Cutte L, Garlick RB, West MJ (2006) Vascular remodeling in the internal mammary artery graft and association with in situ endothelin-1 and receptor expression. Circulation 113:1180–1188
Bern HA, Pearson D, Larson BA, Nishioka RS (1985) Neurohormones from fish tails: the caudal neurosecretory system. I. “Urophysiology” and the caudal neurosecretory system of fishes. Recent Prog Horm Res 41:533–552
Douglas SA, Ohlstein EH (2000) Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10:229–237
Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP (2004) Cellular distribution of immunoreactive urotensin-II in human tissue with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25:1767–1774
Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A (2004) Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176:117–123
Lapp H, Boerrigter G, Costello-Boerrigter LC, Jaekel K, Scheffold T, Krakau I, Schramm M, Guelker H, Stasch JP (2004) Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94:93–97
Ng LL, Loke I, O’Brien RJ, Squire IB, Davies JE (2002) Plasma urotensin in human systolic heart failure. Circulation 106:2877–2880
Richards AM, Nicholls MG, Lainchbury JG (2002) Plasma urotensin II in heart failure. Lancet 360:545–546
Russell FD, Meyers D, Galbraith AJ (2003) Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285:H1576–1581
Heringlake M, Kox T, Uzun O, Will B, Bahlmann L, Klaus S, Eleftheriadis S, Armbruster FP, Franz N, Kraatz E (2004) The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121:129–136
Hongfang J, Bailin C, Bin Z, Chunyu ZH, Xinmin L, Weijin ZH, Ying SH, Chaoshu T, Junbao D (2006) Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 78:1299–1309
Sainani GS, Maru VG, Mehra AP (2005) Role of endothelin-1 in genesis of coronary artery disease. Indian Heart J 57:121–127
Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr(1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325:997–1001
Malek AM, Zhang J, Jiang J, Alper SL, Izumo S (1999) Endothelin-1 gene suppression by shear stress: pharmacological evaluation of the role of tyrosine kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J Mol Cell Cardiol 31:387–399
Ziegler T, Bouzourene K, Harrison VJ, Brunner HR, Hayoz D (1998) Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler Thromb Vasc Biol 18:686–692
Ketonen J, Mervaala E (2008) Effect of dietary sodium on reactive oxygen species formation and endothelial dysfunction in low-density lipoprotein receptor-deficient mice on high-fat diet. Heart Vessels 23:420–429
Niccoli G, Lanza GA, Shaw S, Romagnoli E, Romagnoli E, Gioia D, Burzotta F, Trani C, Mazzari MA, Mongiardo R, DeVita M, Rebuzzi AG, Lüscher TF, Crea F (2006) Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. Eur Heart J 27:1793–1798
Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A (2005) A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Moll Cell Cardiol 39:785–791
Birker-Robaczewska M, Boukhadra C, Studer R, Mueller C, Binkert C, Nayler O (2003) The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 23:289–305
Chen MC, Chen CJ, Yang CH, Wu CJ, Fang CY, Hsieh YK, Chang HW (2007) Interleukin-18: a strong predictor of the extent of coronary artery disease in patients with unstable angina. Heart Vessels 22:371–375
Shirai N, Naruko T, Ohsawa M, Ikura Y, Sugama Y, Hirayama M, Kitabayashi C, Ehara S, Inoue T, Itoh A, Haze K, Tanzawa K, Yoshiyama M, Yoshikawa J, Ueda M (2006) Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. J Hypertens 24:711–721
Yip HK, Wu CJ, Chang HW, Yang CH, Yu TH, Chen YH, Hang CL (2005) Prognostic value of circulating levels of endothelin-1 in patients after acute myocardial infarction undergoing primary coronary angioplasty. Chest 127:1491–1497
MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH (2000) Contractile response to human urotensin II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130: 201–204
Thanassoulis G, Huyhn T, Giaid A (2004) Urotensin II and cardiovascular disease. Peptide 25:1789–1794
Lamarre NS, Tallarida RJ (2008) A quantitative study to assess synergistic interaction between urotensin II and angiotensin II. Eur J Pharmacol 586:350–351
Ahlborg G, Shemyakin A, BÖhm F, Gonon A, Pernow J (2007) Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 30:591–596
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chai, S.B., Li, X.M., Pang, Y.Z. et al. Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. Heart Vessels 25, 138–143 (2010). https://doi.org/10.1007/s00380-009-1178-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00380-009-1178-6